Year: 2021
Type: review
Abstract: c-Myc is a transcription factor that is constitutively and aberrantly expressed in over 70% of human cancers. Its direct inhibition has been shown to trigger rapid tumor regression in mice with only mild and fully reversible side effects, suggesting this to be a viable therapeutic strategy. Here we reassess the challenges of directly targeting c-Myc, evaluate lessons learned from current inhibitors, and explore how future strategies such as miniaturisation of Omomyc and targeting E-box binding could facilitate translation of c-Myc inhibitors into the clinic.
Source: Molecular Cancer
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $4,480
Awards: Irreversibly Silencing Oncogenic Master-regulator cMyc Using Library-derived Electrophilic Helical Peptides, From Peptides to Mimetics: Towards Smaller More Stable Drug-like Protein-protein Interaction Inhibitors, ARC Centre of Excellence in Advanced Molecular Imaging, Modulating Protein-Protein Interactions In Disease, G4760630197, G6642548125, A Generalised Approach to Derive Functionally Active Peptide Inhibitors of Transcription Factor Activity, G8609205739
OpenAlex ID: W3109004530
